4 recruiting, 3 completed. 4 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Recruiting 3, Completed 1 |
| Phase 1 | 3 | Completed 2, Recruiting 1 |
Follow MPNST: new trials by email Literature Review of MPNST trials Research Report on MPNST
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas Selumetinib + ZEN-3694 ± Durvalumab - MPNST, NF1 | Phase 2 | Recruiting | University of Alabama at Birmingham | 41 | 2026-08-04 | 2026-08-24 |
| Safety and Efficacy of BMS-986504 in Unresectable Malignant Peripheral Nerve Sheath Tumor BMS-986504 - Malignant Peripheral Nerve Sheath Tumors, MPNST | Phase 1 / Phase 2 | Recruiting | Ankit Mangla, MD | 17 | 2026-08-01 | 2026-08-11 |
| DoD Award NF230020 Identification of Metabolic Markers and Statistical Prediction of MPNST for Rapid Diagnosis and Assessment of Surgical Margins Neurofibromas, MPNST | Recruiting | M.D. Anderson Cancer Center | 60 | 2026-04-02 | 2026-09-18 | |
| A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors Selinexor - Wilms Tumor, Rhabdoid Tumor | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 45 | 2023-08-01 | 2026-10-23 |
| Transformation of Plexiform Neurofibromas to Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1 MRI, FDG-PET/CT scans, [18F]-FLT-PET/CT scans - Neurofibromatosis, MPNST | Phase 1 | Completed | National Cancer Institute (NCI) | 10 | 2014-12-08 | 2026-10-16 |
| SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors everolimus, bevacizumab - Malignant Peripheral Nerve Sheath Tumors, MPNST | Phase 2 | Completed | Sarcoma Alliance for Research through Collaboration | 25 | 2012-09-01 | 2019-03-06 |
| Comparison of Filgrastim and Filgrastim SD/01in Boosting White Cell Counts After Intensive Chemotherapy Filgrastim, Filgrastim-SD/01 - Ewing's Sarcoma, Rhabdomyosarcoma | Phase 1 | Completed | National Cancer Institute (NCI) | 34 | 2000-03-03 | 2019-11-12 |
Neurofibrosarcoma (7) · Sarcoma (3) · Neoplasms (1) · Neurofibroma (1) · Neurofibromatoses (1) · Neurofibromatosis 1 (1) · Rhabdoid Tumor (1) · Rhabdomyosarcoma (1) · Sarcoma, Ewing (1) · Sarcoma, Synovial (1) · Wilms Tumor (1)
Fibrosarcoma (7) · Neoplasms by Histologic Type (7) · Neoplasms, Connective Tissue (7) · Neoplasms, Connective and Soft Tissue (7) · Neoplasms, Fibrous Tissue (7) · Neoplasms, Nerve Tissue (7) · Nerve Sheath Neoplasms (7) · Nervous System Diseases (7) · Nervous System Neoplasms (7) · Neuromuscular Diseases (7) · Peripheral Nervous System Diseases (7) · Peripheral Nervous System Neoplasms (7) · Neoplasms (6) · Neurofibroma (6) · Sarcoma (4)
AZD 6244 (1) · Bevacizumab (1) · Everolimus (1) · Filgrastim (1) · Magnetic Resonance Spectroscopy (1) · pegfilgrastim (1) · selinexor (1)
National Cancer Institute (NCI) (2) · Ankit Mangla, MD (1) · M.D. Anderson Cancer Center (1) · Memorial Sloan Kettering Cancer Center (1) · Sarcoma Alliance for Research through Collaboration (1) · University of Alabama at Birmingham (1)
United States (7)
Ankit Mangla, MD (1) · Brigitte C Widemann, M.D. (1) · Brigitte C. Widemann, MD (1) · Crystal L Mackall, M.D. (1) · Keila Torres, MD,PHD (1) · Michael Ortiz, MD (1)